House Bill 1873
117th Congress(2021-2022)
Advancing Education on Biosimilars Act of 2021
Introduced
Introduced in House on Mar 12, 2021
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1873
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
March 12, 2021
Sort by most recent
03/16/2021
Referred to the Subcommittee on Health.
03/12/2021
Referred to the House Committee on Energy and Commerce.
03/12/2021
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:48:16 PM